Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Description

In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-230011 Approved October 2023.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Anita Munoz

Dr Anita Munoz

Muscle Health in Chronic Disease: A Practical Guide for GPs

Prof Brendon Yee

Prof Brendon Yee

Obstructive Sleep Apnoea & Driving: The GP's Role

Dr Adam Nelson

Dr Adam Nelson

Why is LDL Control Important?

Dr Terri Foran

Dr Terri Foran

Non-Hormonal & Hormonal Options for Hot Flushes

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Martin MacDonald

expert

Dr Martin MacDonald

Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital

Date published: 20 November 2023